Gapping down
In reaction to disappointing earnings/guidance: GEF -6.2%, QIHU -3.9%.
Other news: RGDO -44% (permanently halts REGULATE-PCI clinical trial), CGEN -1.2% (disclosed it appointed Ari Krashin as Chief Financial Officer effective as of September 9, 2014), OKS -0.9% (files for $650 mln offering of common units representing limited partner interests).
Analyst comments: STLD -1.7% (downgraded to Neutral at from Outperform Credit Suisse)
.
In reaction to disappointing earnings/guidance: GEF -6.2%, QIHU -3.9%.
Other news: RGDO -44% (permanently halts REGULATE-PCI clinical trial), CGEN -1.2% (disclosed it appointed Ari Krashin as Chief Financial Officer effective as of September 9, 2014), OKS -0.9% (files for $650 mln offering of common units representing limited partner interests).
Analyst comments: STLD -1.7% (downgraded to Neutral at from Outperform Credit Suisse)
.